Ledyard National Bank boosted its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 3,884.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,563 shares of the biopharmaceutical company’s stock after buying an additional 9,323 shares during the period. Ledyard National Bank’s holdings in Regeneron Pharmaceuticals were worth $3,927,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Joel Isaacson & Co. LLC increased its position in shares of Regeneron Pharmaceuticals by 0.8% during the first quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $1,249,000 after acquiring an additional 25 shares during the period. Diversified Trust Co increased its holdings in Regeneron Pharmaceuticals by 0.8% in the fourth quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock valued at $1,356,000 after buying an additional 30 shares during the last quarter. Kaizen Advisory LLC increased its holdings in Regeneron Pharmaceuticals by 21.2% in the fourth quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 35 shares during the last quarter. Whittier Trust Co. increased its holdings in Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. Finally, AdvisorNet Financial Inc increased its holdings in Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 52 shares during the last quarter. Institutional investors and hedge funds own 67.03% of the company’s stock.
Several equities analysts have issued reports on the company. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 8th. BidaskClub lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals to $412.00 and gave the stock a “market perform” rating in a report on Thursday, February 7th. Guggenheim downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. Finally, Jefferies Financial Group decreased their target price on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a research note on Wednesday, April 17th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $413.94.
Shares of REGN traded up $1.48 during mid-day trading on Friday, reaching $336.89. 810,083 shares of the company’s stock were exchanged, compared to its average volume of 748,789. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.47 and a quick ratio of 3.67. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $442.00. The stock has a market cap of $36.65 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 1.33 and a beta of 1.08.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company’s revenue was up 21.9% on a year-over-year basis. During the same period last year, the company posted $5.23 EPS. On average, equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/ledyard-national-bank-boosts-stake-in-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: What is the return on assets (ROA) ratio?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.